RelapsedRefractory

Single-agent pembrolizumab (Keytruda) produced durable responses and encouraging survival in patients with…

Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in cancer treatment, with multiple indications and…

Follow-up data from the EPCORE NHL-1 trial lend further support to the efficacy and safety of…

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and…

CHICAGO -- More than 70% of patients with heavily pretreated multiple myeloma had responses to the novel…

CHICAGO -- Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel…

- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no…

The FDA granted accelerated approval to epcoritamab (Epkinly) for the treatment of adults with relapsed or…

The combination of venetoclax (Venclexta) and lenalidomide (Revlimid) was shown to be tolerable and…

A first-in-class bispecific antibody achieved durable responses in a fourth of patients with…